First, we look for sources
We use study reports and information from medicine regulators. When we use a manufacturer's announcement, we say so clearly. The number beside a sentence links to its source.
We also say whether we read the full article or only its summary. We do not claim to know content we could not access.
What did we check, and what did we not check?
We checked the sources and the figures quoted. We have not read every paper on each topic.
We explain what is known and what remains unknown. We do not select treatment or doses for an individual.
What does the date on an article mean?
The day we checked the information used. It does not mean the site continuously monitors new research. Important changes require another review of the sources.
We write for people without medical knowledge
We use everyday words and short sentences. We explain difficult terms straight away and illustrate numbers with examples. Detailed data and study names are kept in expandable sections.
2 November 2026: we prepared separate profiles and news pages for semaglutide, tirzepatide and retatrutide. They are for adults without medical training: clear, factual and with necessary terms explained. We also completed separate profiles and articles for BPC-157, TB-500, MOTS-c and GHK-Cu. Where evidence is weaker, we state the unknowns clearly; research interest alone does not establish a use.